Cargando…

Radiation dose escalation with modified fractionation schedules for locally advanced NSCLC: A systematic review

Concomitant chemo‐radiotherapy (cCRT) with 60 Gy in 30 fractions is the standard of care for stage 111 non‐small cell lung cancer (NSCLC). With a median overall survival of 28.7 months at best and maximum locoregional control rates of 70% at two years, the prognosis for these patients is still disma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zehentmayr, Franz, Grambozov, Brane, Kaiser, Julia, Fastner, Gerd, Sedlmayer, Felix
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2020
Materias:	Invited Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262927/ https://www.ncbi.nlm.nih.gov/pubmed/32323484 http://dx.doi.org/10.1111/1759-7714.13451

Ejemplares similares

High Dose Thoracic Re-Irradiation and Chemo-Immunotherapy for Centrally Recurrent NSCLC
por: Grambozov, Brane, et al.
Publicado: (2022)

Chemo-Radio-Immunotherapy for NSCLC III: ESR/ATS Thresholds for DL(CO) Correlate with Radiation Dosimetry and Pneumonitis Rate
por: Stana, Markus, et al.
Publicado: (2023)

Pulmonary function decreases moderately after accelerated high‐dose irradiation for stage III non‐small cell lung cancer
por: Grambozov, Brane, et al.
Publicado: (2019)

Re-Irradiation for Locally Recurrent Lung Cancer: A Single Center Retrospective Analysis
por: Grambozov, Brane, et al.
Publicado: (2021)

Impact of reirradiation, chemotherapy, and immunotherapy on survival of patients with recurrent lung cancer: A single‐center retrospective analysis
por: Grambozov, Brane, et al.
Publicado: (2021)

Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Trospective Comparison Focusing on Pulmonary Toxicity
por: Wass, Romana, et al.
Publicado: (2022)

Hsa-miR-375/RASD1 Signaling May Predict Local Control in Early Breast Cancer
por: Zellinger, Barbara, et al.
Publicado: (2020)

Carbon Monoxide Diffusing Capacity (DL(CO)) Correlates with CT Morphology after Chemo-Radio-Immunotherapy for Non-Small Cell Lung Cancer Stage III
por: Stana, Markus, et al.
Publicado: (2022)

Hsa-miR-3651 could serve as a novel predictor for in-breast recurrence via FRMD3
por: Zellinger, Barbara, et al.
Publicado: (2021)

Survival in early lung cancer patients treated with high dose radiotherapy is independent of pathological confirmation
por: Zehentmayr, Franz, et al.
Publicado: (2019)

DART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily)–a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume
por: Wurstbauer, Karl, et al.
Publicado: (2013)

Boost IORT in Breast Cancer: Body of Evidence
por: Sedlmayer, Felix, et al.
Publicado: (2014)

Intraoperative radiotherapy (IORT) as boost in breast cancer
por: Sedlmayer, Felix, et al.
Publicado: (2017)

DART-bid for loco-regionally advanced NSCLC: Summary of acute and late toxicity with long-term follow-up; experiences with pulmonary dose constraints
por: Wurstbauer, Karl, et al.
Publicado: (2017)

Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid)
por: Zehentmayr, Franz, et al.
Publicado: (2015)

Hsa-miR-375 is a predictor of local control in early stage breast cancer
por: Zehentmayr, Franz, et al.
Publicado: (2016)

Reply to: The challenge of cardiac dose constraint adaptation to hypofractionated breast radiotherapy in clinical practice
por: Piroth, Marc D., et al.
Publicado: (2021)

miR-16-5p Is a Stably-Expressed Housekeeping MicroRNA in Breast Cancer Tissues from Primary Tumors and from Metastatic Sites
por: Rinnerthaler, Gabriel, et al.
Publicado: (2016)

Nonmetastatic pancreatic cancer: Improved survival with chemoradiotherapy > 40 Gy after systemic treatment
por: Bachmayer, Sebastian, et al.
Publicado: (2018)

The Impact of Radiation on the Tumor Microenvironment: Effect of Dose and Fractionation Schedules
por: Arnold, Kimberly M, et al.
Publicado: (2018)

PET-Plan: potential for dose escalation by target volume reduction in locally advanced NSCLC
por: de Jong, Evelyn E. C., et al.
Publicado: (2020)

Preoperative chemoradiation for locally advanced rectal cancer: comparison of three radiation dose and fractionation schedules
por: Park, Shin-Hyung, et al.
Publicado: (2016)

Phase I dose-escalation oncology trials with sequential multiple schedules
por: Günhan, Burak Kürsad, et al.
Publicado: (2021)

Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules?
por: Shibamoto, Yuta, et al.
Publicado: (2016)

Comparison of Survival Outcomes of Single- and Five-Fraction Schedules of Stereotactic Body Radiation Therapy for Early-Stage Central or Peripheral NSCLC
por: Huang, Karen, et al.
Publicado: (2023)

First clinical application of image-guided intraoperative electron radiation therapy with real time intraoperative dose calculation in recurrent rectal cancer: technical procedure
por: Roeder, Falk, et al.
Publicado: (2023)

Radiation treatment planning with embedded dose escalation
por: Hrinivich, William T., et al.
Publicado: (2019)

National trends in radiation dose escalation for glioblastoma
por: Wegner, Rodney E., et al.
Publicado: (2019)

A Phase I Dose-Escalation Trial of Single-Fraction Stereotactic Radiation Therapy for Liver Metastases
por: Meyer, Jeffrey J., et al.
Publicado: (2015)

Escalator: An Autonomous Scheduling Scheme for Convergecast in TSCH
por: Oh, Sukho, et al.
Publicado: (2018)

A comparative study of different dose fractionations schedule of thoracic radiotherapy for pain palliation and health-related quality of life in metastatic NSCLC
por: Sau, Sourav, et al.
Publicado: (2014)

ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
por: Du, Xue, et al.
Publicado: (2018)

The role of Cobalt-60 in modern radiation therapy: Dose delivery and image guidance
por: Schreiner, L. John, et al.
Publicado: (2009)

Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation
por: Repka, Michael C., et al.
Publicado: (2017)

Clinical Outcomes of Dose-Escalated Hypofractionated External Beam Radiation Therapy (5 Gy × 5 Fractions) for Spine Metastasis
por: Shin, Jacob Y., et al.
Publicado: (2022)

Dose escalation of radiation therapy with or without induction chemotherapy for unresectable locally advanced pancreatic cancer
por: Ma, Sung Jun, et al.
Publicado: (2018)

Assessment of response to neoadjuvant radiochemotherapy with F-18 FLT and F-18 FDG PET/CT in patients with rectal cancer
por: Rendl, Gundula, et al.
Publicado: (2014)

Presentation of treatment effect in glioblastoma after dose-escalation radiation therapy
por: Cicka, Danielle, et al.
Publicado: (2019)

Dose and fractionation schedules in radiotherapy for non-small cell lung cancer
por: Kepka, Lucyna, et al.
Publicado: (2021)

What does a modified-Fibonacci dose-escalation actually correspond to?
por: Penel, Nicolas, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_l5iu1a036n089mn19rfond6r1i